Status:
RECRUITING
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants
Lead Sponsor:
Jiangsu Province Centers for Disease Control and Prevention
Conditions:
Pertussis
Diphtheria
Eligibility:
All Genders
19-22 years
Phase:
NA
Brief Summary
The main purpose of this study is to evaluate immune persistence at 30 and 36 Months of Age and Pertussis Breakthrough Infections between 19 and 36 Months of Age following two regiments of DTaP-IPV/Hi...
Detailed Description
This study was based on the DTaP-IPV/Hib Pentavalent Vaccine Basic Immunization Strategy Optimization Study Cohort ("Pentavalent Vaccine Cohort") and the Epidemiological Investigation of Carrying Stat...
Eligibility Criteria
Inclusion
- \- (1)Received 4 doses of DTaP-IPV/Hib pentavalent vaccines (2) Obtained consent from the participant's caregiver and sign an informed consent form
Exclusion
- (1) Diagnosed by a physician with a coagulation abnormality (e.g., coagulation factor deficiency, coagulopathy, platelet abnormality) (2) Any other factor considered to make participation in the trial unsuitable.
Key Trial Info
Start Date :
September 5 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
785 Patients enrolled
Trial Details
Trial ID
NCT06605755
Start Date
September 5 2024
End Date
February 1 2026
Last Update
September 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jingsu Provincial Centre of Disease Control and Prevention
Nanjing, Jiangsu, China, 210009